Hjem › Neuroblastom › Ohio
Neuroblastom kliniske forsøg i Ohio
8 studier for Neuroblastom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- og 4 flere
RekruttererFase 3
Op til 30 år · Alle køn · Opdateret 2. okt. 2026 · NCT06172296Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- og 3 flere
RekruttererFase 3
365 Days – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT04851119Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 2
Alder 1 til 39 · Alle køn · Opdateret 24. aug. 2026 · NCT07635056SPEARHEAD-3 Pediatric Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1/2
Alder 2 til 21 · Alle køn · Opdateret 11. aug. 2026 · NCT05642455NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
Alder 1 til 31 · Alle køn · Opdateret 20. jul. 2026 · NCT06450041Neuroblastoma Biology Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererObservationsstudie
31 Days – 99 Years · Alle køn · Opdateret 23. mar. 2026 · NCT01587300A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
18 Months – 40 Years · Alle køn · Opdateret 12. aug. 2025 · NCT05135975Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.